Publication | Closed Access

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Non-small-cell Lung CancerMedicinePharmacologyImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentCheckmate 9LaOncologyLung Cancer